201. Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice.
- Author
-
Yu SH, Dubey NK, Li WS, Liu MC, Chiang HS, Leu SJ, Shieh YH, Tsai FC, and Deng WP
- Subjects
- Animals, Biological Products chemistry, Collagen analysis, Diabetes Mellitus, Experimental blood, Diabetes Mellitus, Experimental complications, Diabetes Mellitus, Experimental physiopathology, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 physiopathology, Diabetic Nephropathies blood, Diabetic Nephropathies complications, Diabetic Nephropathies physiopathology, Fruiting Bodies, Fungal chemistry, Glycation End Products, Advanced analysis, Glycogen analysis, Hypoglycemic Agents chemistry, Kidney physiopathology, Kidney Function Tests, Mice, Mice, Inbred C57BL, Mycelium chemistry, Streptozocin, Transforming Growth Factor beta1 analysis, Biological Products therapeutic use, Cordyceps chemistry, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Type 2 drug therapy, Diabetic Nephropathies drug therapy, Hypoglycemic Agents therapeutic use, Kidney drug effects
- Abstract
Diabetic nephropathy is derived from long-term effects of high blood glucose on kidney function in type 2 diabetic patients. Several antidiabetic drugs and herbal medications have failed to prevent episodes of DN. Hence, this study aimed to further investigate the renal injury-reducing effect of antidiabetic CmNo1, a novel combination of powders of fruiting bodies and mycelia of Cordyceps militaris. After being administered with streptozotocin-nicotinamide and high-fat-diet, the diabetic nephropathy mouse model displayed elevated blood glucose and renal dysfunction markers including serum creatinine and kidney-to-body weight ratio. These elevated markers were significantly mitigated following 8 weeks CmNo1 treatment. Moreover, the chronic hyperglycemia-induced pathological alteration in renal tissue were also ameliorated. Besides, immunohistochemical study demonstrated a substantial reduction in elevated levels of carboxymethyl lysine, an advanced glycation end product. Elevated collagenous deposition in DN group was also attenuated through CmNo1 administration. Moreover, the enhanced levels of transforming growth factor-β1, a fibrosis-inducing protein in glomerulus were also markedly dampened. Furthermore, auxiliary risk factors in DN like serum triglycerides and cholesterol were found to be increased but were decreased by CmNo1 treatment. Conclusively, the results suggests that CmNo1 exhibit potent and efficacious renoprotective action against hyperglycemia-induced DN., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF